Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of trimetazidine on endothelial function and prognosis biomarkers in HFpEF
2023-506138-65-00Phase 4Completed
- Sponsor
- Medical University of Gdańsk
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Trimetazidine arm with Placebo arm (2 arms). Primary endpoint: Time to hospitalization due to heart failure exacerbation or cardiovascular death. Started Jan 2024; status: completed.
02
Drugs
trimetazidine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-506138-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506138-65-00.